Vorolanib (CM082; X-82) 是一种具有口服活性的 VEGFR/PDGFR 抑制剂。Vorolanib 最大限度地降低了毒性，破坏肿瘤的血管生成和肿瘤细胞增殖，并诱导肿瘤细胞死亡。
| Cas No. | 1013920-15-4 |
| 别名 | CM082; X-82 |
| Canonical SMILES | O=C1/C(C2=CC(F)=CC=C2N1)=C/C(NC(C)=C3C(N[C@@H]4CN(C(N(C)C)=O)CC4)=O)=C3C |
| 分子式 | C23H26FN5O3 |
| 分子量 | 439.48 |
| 溶解度 | DMSO: 27 mg/mL (61.44 mM) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Vorolanib (CM082; X-82) is an orally active, multikinase VEGFR/PDGFR inhibitor. Vorolanib minimizes toxicity, disrupts tumor angiogenesis and tumor cell proliferation, and induces of tumor cell death[1]. [1]. Bendell JC, et al. Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors. Oncologist. 2019 Apr;24(4):455-e121. |
